Program
lorigerlimab
Also written as “Lorigerlimab”.
Its studies are mostly in Prostatic Neoplasms, Castration-Resistant · Endometrial Neoplasms · Melanoma, led by MacroGenics.
Furthest: phase 2, since Apr 17, 20234 company-led studies, 1 open or runningNext primary completion: Jul 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| MacroGenics | 41 open or running | phase 2since Apr 17, 2023 | Nov 29, 2018 | Jul 2027phase 2 · NCT06730347 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 29, 2018First study: phase 1 study in MelanomaFirst studyNCT03761017 · 162 enrolled · United States, Bulgaria, Poland and more
- Feb 12, 2022Phase 1 study in Prostatic Neoplasms, Castration-ResistantNCT05293496 · 31 enrolled · United States
- Apr 17, 2023Phase 2 study in Prostatic Neoplasms, Castration-ResistantNCT05848011 · 154 enrolled · United States, Australia, Belgium and more
- Dec 9, 2024Phase 2 study in Endometrial NeoplasmsNCT06730347 · 80 planned · United States, Canada, South Korea
Ahead
- Jul 2027Primary completion: phase 2 study in Endometrial NeoplasmsNCT06730347
TargetBeta
“A hinge stabilized immunoglobulin G4 (IgG4) tetravalent bispecific antibody-like protein directed against the human negative immunoregulatory checkpoint receptors programmed cell death protein 1 (PD-1; PDCD1; CD279) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), ”NCIt, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| cadonilimabrule | Akeso | phase 3 | 45 |
| Iparomlimab/Tuvonralimabrule | Qilu Pharmaceutical | phase 3 | 22 |
| volrustomig | AstraZeneca | phase 3 | 19 |
| Anti-PD-1/Anti-CTLA-4/Anti-VEGF Trispecific Antibody HC010rule | hc-biopharma-inc | phase 2 | 2 |
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06730347Endometrial Neoplasms · United States, Canada, South Korea | 2 | Recruiting | Jul 2027 | 80 |
| NCT05848011Prostatic Neoplasms, Castration-Resistant · United States, Australia, Belgium and more | 2 | Completed | Feb 19, 2026 | 154 |
| NCT05293496Prostatic Neoplasms, Castration-Resistant · United States | 1 | Completed | Jun 24, 2025 | 31 |
| NCT03761017Melanoma · United States, Bulgaria, Poland and more | 1 | Completed | Aug 29, 2024 | 162 |
How it is read
Names in the registry
- “Lorigerlimab”, 2 entries
- “lorigerlimab”, 2 entries
Conditions, from the studies’ own filings
- Prostatic Neoplasms, Castration-Resistant, 2 studies
- Endometrial Neoplasms, 1 study
- Melanoma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.